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ABSTRACT
Human Thymine-DNA Glycosylase (TDG) is a
member of the uracil DNA glycosylase (UDG) super-
family. It excises uracil, thymine and a number of
chemical base lesions when mispaired with guanine
in double-stranded DNA. These activities are not
unique to TDG; at least three additional proteins
with similar enzymatic properties are present in
mammalian cells. The successful co-evolution of
these enzymes implies the existence of non-
redundant biological functions that must be coordi-
nated. Here, we report cell cycle regulation as a
mechanism for the functional separation of appar-
ently redundant DNA glycosylases. We show that
cells entering S-phase eliminate TDG through the
ubiquitin–proteasome system and then maintain a
TDG-free condition until G2. Incomplete degrada-
tion of ectopically expressed TDG impedes S-phase
progression and cell proliferation. The mode of cell
cycle regulation of TDG is strictly inverse to that of
UNG2, which peaks in and throughout S-phase
and then declines to undetectable levels until it
appears again just before the next S-phase.
Thus, TDG- and UNG2-dependent base excision
repair alternates throughout the cell cycle, and
the ubiquitin–proteasome pathway constitutes the
underlying regulatory system.
INTRODUCTION
Uracil (U) arises in DNA either by erroneous incorpora-
tion of dUMP opposite adenine (A) during DNA
synthesis or by deamination of cytosine (C), which
generates a U mispaired with guanine (G). To what
extent A U base pairs aﬀect the function of DNA is
unclear; G U mispairs, however, give rise to C!T
mutations if a DNA polymerase replicates across. Uracil
DNA glycosylases (UDGs) (1) have evolved to eliminate
this irregular base from the DNA. They hydrolyze the
N-glycosidic bond linking the U to the sugar moiety of the
nucleotide, thereby initiating a base excision repair (BER)
process (2) that restores the canonical Watson–Crick base
pair. Mammalian cells posses at least four enzymes with
UDG activity, namely UNG, TDG, SMUG1 and MBD4
(3–6), and the successful co-evolution of these enzymes
implies that each of them fulﬁls speciﬁc non-redundant
biological functions. The question then is how cells
achieve the functional separation of these enzymatically
redundant activities. One way would be to control their
spatial and temporal distribution as exempliﬁed by the
UNG proteins. Diﬀerential expression of the human UNG
gene from two alternative promoters generates two
isoforms, UNG1 and UNG2, that localize to mitochon-
dria and to nuclei, respectively (7). Moreover, UNG2
expression is up-regulated during S-phase of the cell cycle
where the protein associates with PCNA and RPA at
replication foci, implicating a role for this UDG in the
removal of misincorporated U during DNA replication
(8,9). Whether similar forms of regulation apply
to other UDGs and, thus, could provide a cellular
mechanism for functional coordination of uracil repair is
not known. Here, we report that Thymine-DNA
Glycosylase (TDG), a mismatch-speciﬁc UDG, underlies
strict cell cycle regulation. TDG has a comparably broad
substrate spectrum including the deamination product of
5-methylcytosine, i.e. a T mispaired with a G, but its
most eﬃciently processed physiological substrate is a G U
mispair (6). Cells entering S-phase eliminate this glycosy-
lase through the ubiquitin–proteasome pathway and
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completed. Degradation of TDG is critical for S-phase
progression and cell proliferation, implicating that this
UDG interferes negatively with vital processes of DNA
replication. Strikingly, TDG levels decline just when
UNG2 expression comes up and vice versa, suggesting
that uracil repair is handled by distinct pathways
throughout the cell cycle that are coordinated by the
ubiquitin–proteasome system.
MATERIAL AND METHODS
Reagents andantibodies and expression constructs
The complete
TM protease inhibitor tablets were purchased
from Roche (Switzerland). All other chemicals and
reagents were from Sigma (Germany). All media and
supplements used for cell culture were purchased from
Gibco BRL (Invitrogen, UK). The polyclonal and
monoclonal (99) anti-TDG antibodies were described
earlier (Hardeland et al., 2002), anti-ubiquitin (P4D1)
and anti-cyclin B1 (GNS 1) antibodies were from Santa
Cruz Biotechnology, Inc. (CA, USA), anti-HA (3F10)
antibody from Roche (Switzerland), anti cyclin A
(BF 683) from Milliporee (MA, USA) and anti-cyclin E
(Ab-1, Ab-2) antibodies from Labvision (CA, USA),
and anti-UNG (ab23926) and anti MBD4 (ab12187)
antibodies from Abcam (UK). The anti-b-tubulin anti-
body (N37) and the secondary horse-radish-peroxidase
conjugated antibodies were purchased from GE
Healthcare Life Sciences (Germany). The plasmid
constructs expressing HA-TDG or HA-TDG
N140A have
been previously described (10).
Cellculturing,cellcyclesynchronizations,proteinextractions
MRC5 cells were cultured in Nutrition Mix Ham’s F-10
medium with Glutamax I, HeLa, HeLa S3 and 293T cells
were grown in Dulbecco’s modiﬁed Eagle’s (DMEM)
medium containing 2mM L-glutamine, both supplemen-
ted with 10% fetal calf serum and antibiotics (penicillin/
streptomycin). For HeLa cells stably or transiently
transfected with TDG expression constructs, the medium
was supplemented with 0.8 or 0.2mg/ml puromycin,
respectively. Stably transfected 293T cells were grown in
the presence of 1.5mg/ml puromycin. All cultures were
incubated at 378C in a humidiﬁed atmosphere containing
5% CO2. All transfections were done at 30% conﬂuency
with 1mg (HeLa cells) or 8mg (293T cells) of vector
DNA using the Fugene reagent (Roche, Switzerland).
The eﬃciency of plasmid delivery was estimated by
transfection of pEGFP-N1 (Clontech, USA) under
identical conditions and quantitation of EGFP positive
cells by ﬂuorescence microscopy. Transiently transfected
cells were cultured for 48h unless stated otherwise.
For cell cycle analysis, 293T cells were seeded onto
microscope slides at a conﬂuency of 50% and allowed to
attach for 7h in medium at 378C. The slides were then
washed three times in PBS and cells ﬁxed in acetone for
2min at  208C. After short rehydration with PBS, the
slides were covered with staining solution (50mg/ml
propidium iodide, 200mg/ml RNaseA) and incubated for
30min at 378C in a humidiﬁed chamber. After quick
rinsing in PBS, the slides were covered with 50% glycerol
in PBS and a coverslip and their DNA content analysed
on a laser scanning cytometer, LSC-1 (LSC CompuCyte,
USA). In parallel, cell cycle analyses were done by
standard ﬂow cytometry.
Cell cycle arrest experiments were performed by
treatment of 5 10
6 HeLa cells at 50% conﬂuency with
either 2.5mM hydroxyurea (HU, 2M stock in H2O),
0.8mg/ml nocodazole (NO, 1mg/ml stock in DMSO) or
respective amounts of DMSO only. After 16h, denaturing
extracts were prepared by scraping cells from the culture
plates in 400ml of lysis buﬀer I (8M urea, 200mM DTT,
120mM Tris/HCl pH 6.8, 4% SDS, 20% glycerol, 0.01%
bromphenolblue) and heating for 10min at 958C. Equal
sample volumes were then analysed by 10% SDS–
polyacrylamide-gel-electrophoresis (SDS-PAGE) and
western blotting. HeLa S3 cells were synchronized by
harvesting and reseeding detached mitotic cells as follows.
Cells were ﬁrst cultured to 70% conﬂuency in 8 ﬂasks of
175cm
2 size. To remove all loosely attaching cells, the
cultures were extensively washed with pre-warmed
medium. The washing procedure was repeated after
another 2h of incubation. After further 2h, the medium
containing detached mitotic cells was removed and cells
collected by centrifugation. 1.3 10
6 cells per time point
were replated and grown for the times indicated. At each
time point, cells were washed with 1  PBS pH 7.4 on the
plate and the proteins extracted by direct lysis in 200ml
lysis buﬀer I. Equal amounts of extract were then analysed
by SDS-PAGE and western blotting. MRC5 cells were
synchronized by serum starvation followed by mimosine
treatment as described in (11). After release, samples were
taken at diﬀerent time points and cell extracts prepared for
western blotting (11).
For proteasome inhibition 5 10
6 HeLa cells at 50%
conﬂuency were treated for 12h with 20mM MG132
(20mM stock in DMSO) or an equivalent of DMSO only.
The cells were then washed with PBS and directly lysed by
addition of 400ml lysis buﬀer I. For the preparation of
soluble and insoluble protein fractions 2.5 10
7 MG132
treated cells were lysed with 2ml of lysis buﬀer II
(50mM Na-phosphate pH 8.0, 125mM NaCl, 1%
NP-40, 0.5mM EDTA, 1mM PMSF, 1  complete
TM
protease inhibitors). Soluble and insoluble proteins were
then separated by centrifugation for 15min at 14000
r.p.m., 48C. After removal of the supernatant (soluble
proteins) the pellet (insoluble proteins) was resuspended in
the same volume. Equal amounts of both fractions were
separated by SDS-PAGE and analysed by western
blotting. Denaturing extracts of MG132 treated cells
were obtained by scraping cells from culture dishes in lysis
buﬀer III (50mM Tris/HCl pH 7.5, 1% SDS, 5mM DTT)
and heating the suspensions for 10min at 958C.
Immunoprecipitation and western blotting
M-280 tosylactivated Dynabeads (Invitrogen, UK) were
coated with aﬃnity puriﬁed rabbit polyclonal anti-TDG
antibody or BSA according to the manufacturer’s proto-
col. An aliquot of 400ml of the denaturing extracts
of MG132 treated HeLa cells was diluted 1:10 in dilution
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ol, 1% NP-40, 1mM EDTA, 1mM PMSF and 1 
complete
TM protease inhibitors) before the addition of
equilibrated Dynabeads ( 2.4 10
7beads/assay). After
incubation for 4h at 48C under rotation, unbound
proteins were removed and the beads washed three times
with dilution buﬀer at 48C. Bound proteins were then
eluted in 40mlo f2   SDS-sample-buﬀer (200mM DTT,
120mM Tris/HCl pH 6.8, 4% SDS, 20% glycerol, 0.01%
bromphenolblue) and incubation at 958C for 5min.
Following protein separation by 8 or 10% SDS-PAGE,
western blotting was done with antibodies against
TDG and ubiquitin following standard procedures.
All antibodies were diluted in TBS-T (100mM Tris/HCl
pH 8.0, 150mM NaCl, 0.1% Tween20) containing 5%
dry milk as blocking reagent; the polyclonal anti-TDG
antiserum was diluted 1:10000, the monoclonal anti-TDG
and anti-ubiquitin antibodies 1:1000. Detection of the
signals was carried out using the enhanced chemilumines-
cent (ECL
TM) substrate system (GE Healthcare Life
Sciences, Germany).
Immunofluorescence
HeLa cells were grown on coverslips to a conﬂuency of
30%. After washing extensively in PBS, the cells were ﬁxed
for 5min in pre-chilled methanol ( 208C), re-hydrated for
4times10min at room temperature (rT) in PBS, and
permeabilized for 5min in ice-cold P-buﬀer (PBS, 0.2%
TritonX100). To reduce autoﬂuorescence, the coverslips
were incubated for another 5min in ice-cold P-buﬀer
containing 0.2% NaBH4. Soluble protein was then washed
out by gently shaking the coverslips in PBS for 10min at
rT. After blocking for 10min at rT in hybridization buﬀer
(PBS, 1% BSA), samples were hybridized with aﬃnity-
puriﬁed polyclonal rabbit anti-TDG- (1:100 dilution) and
a FITC coupled anti-PCNA (1:500, Leinco Technologies,
MO, USA) antibodies at 48C overnight. After four
washing steps of 10min in hybridization buﬀer at rT,
samples were hybridized with an anti-rabbit IgG Alexa-
546 conjugated secondary antibody (1:200, Invitrogen,
UK) at rT for 1h. After four washing steps of 10min
in PBS, the coverslips were dried and embedded in
Mowiol containing 1mg/ml DAPI. TDG and PCNA
signals were visualized on a Axiovert 200M microscope
(Zeiss, Germany) using TRITC (exitation 560nm,
emission 580nm) and FITC (exitation 490, emission
520nm) ﬁlters, respectively.
Northern blot analyses
Total RNA was isolated from MRC5 cells using the
TRIzol reagent. RNA concentrations were determined by
A260 measurement and the quality was checked by
electrophoresis on 1% formaldehyde agarose gels.
Twenty microgram of total RNA in formamide loading
buﬀer were separated in a 1% agarosegel containing
formaldehyde. After washing the gel twice for 10min in
8mM NaOH, the RNA was transferred to a Zeta Probe
membrane (BioRad, CA, USA) overnight in 8mM
NaOH. After a brief washing step with 2  SSC the
transferred RNA was ﬁxed by baking at 808C. Following
pre-hybridization of the membrane at 658Ci n
hybridization buﬀer (0.5M Na2PO4 pH 7.2, 7% SDS)
for 5min, hybridization with probe was done for 20h at
658C. A
32P-labeled PCR fragment (Megaprime Kit, GE
Healthcare Life Sciences, Germany), representing the 50
part of the TDG cDNA served as speciﬁc probe. After
hybridization the membrane was washed twice with wash
buﬀer I (40mM Na2PO4 pH 7.2, 5% SDS) for 20min at
658C, followed by one washing steps with wash buﬀer II
(40mM Na2PO4 pH 7.2, 1% SDS) at 658C for 10min.
After exposition of the membrane to a phosphoimager
screen, signals were visualized on a Storm phosphoimager
(GE Healthcare Life Sciences, Germany).
Ubiquitylation invitro
In vitro ubiquitylation reactions were performed with the
ubiquitin conjugation Enzyme Kit (Biotrend, Germany)
according to the manufacturer’s instructions. An aliquot
of 20ml reactions contained 1  MgATP, 5mg conjugating
fraction I, 5mg conjugation fraction II, 26mg ubiquitin
(Biotrend), 200ng ubiquitin-aldehyde and 10ng of recom-
binant TDG protein. The reactions were incubated at
378C for 0 and 2h and stopped by the addition of 4ml6  
SDS-sample buﬀer (600mM DTT, 360mM Tris/HCl pH
6.8, 12% SDS, 60% glycerol, 0.03% bromphenolblue).
After heating at 958C for 5min the reaction products were
analysed by 7.5% SDS-PAGE and western blotting with
the polyclonal anti-TDG antibody.
Baserelease assays
Nuclear extracts were prepared from 10
8 HeLa cells
harvested after HU (or mock) treatment. Cells were
resuspended in ice-cold hypotonic buﬀer (20mM HEPES
pH 8.0, 5mM KCl, 1.5mM MgCl2, 0.5mM PMSF, 1mM
DTT, 1  complete
TM protease inhibitors) at a cell density
of 1 10
8cells/ml and allowed to swell for 20min on ice.
Cells were broken up in a Dounce homogenizer on ice
to achieve 480% lysis and the liberated nuclei were
harvested by centrifugation at 3000g and 48C. After
estimation of the packed nuclear volume (pnv) the pellet
was resuspended in 1/2 pnv low salt buﬀer (20mM
HEPES pH 8.0, 25% glycerol, 1.5mM MgCl2,2 0 m M
KCl, 0.2mM EDTA, 0.5mM PMSF, 0.5mM DTT,
1  complete
TM protease inhibitors). Nuclear proteins
were extracted by the addition of 1/2 pnv high salt buﬀer
(low salt buﬀer but 0.8M KCl) and incubation at 48C
under constant mixing for 30min. The extracted nuclei
were pelleted for 20min at 20000g and 48C. The super-
natant was dialyzed against storage buﬀer (20mM
HEPES pH 8.0, 10% glycerol, 1.5mM MgCl2,5 m M
KCl, 0.2mM EDTA, 0.5mM PMSF, 0.5mM DTT, 0.25 
complete
TM protease inhibitors). The dialyzed extracts
were clariﬁed by centrifugation for 20min at 20000g and
48C and stored in aliquots at  808C. Protein concentra-
tions were estimated by the Bradford method (BioRad)
using BSA as standard. Base release assays were then done
according to (12) with slight modiﬁcations. An aliquot of
40ml reactions contained 25mg nuclear extracts and
1pmol of either double-stranded homoduplex or mis-
matched DNA substrate (12). The reactions were incu-
bated for 24h at 378C in reaction buﬀer (50mM Tris-HCl
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ing 2 U UGI. Quantitative cleavage of AP sites was
achieved by the addition of 100mM NaOH and heating at
958C for 10min. Subsequently, DNA was ethanol
precipitated overnight at  208C in 0.3M sodium acetate
pH 5.2 and in the presence of 0.4mg/ml carrier tRNA.
The DNA was then pelleted by centrifugation (20min,
20000g,4 8C), washed once in 80% ethanol, air-dried,
resuspended in formamide loading buﬀer (1  TBE, 90%
formamide), heated at 958C for 5min and immediately
chilled on ice. The reaction products were separated by
electrophoresis in preheated 15% denaturing polyacryla-
mide gels and 1  TBE buﬀer. Visualization of the
ﬂuorescein labelled DNA was carried out on a Typhoon
9400 (GE Healthcare, Germany) and the data were
quantiﬁed using the ImageQuant TL software (GE
Healthcare, Germany).
RESULTS
S-phase progression requires cell cycle regulation
ofTDG-mediated BER
We found in diﬀerent human cell models (HeLa, 293T,
MRC5) that expression of high levels of TDG is
incompatible with cell proliferation. Although transfec-
tion of various constructs designed for stable TDG
expression produced transiently up to 30-fold the endo-
genous level, any attempt to maintain expression at levels
above 5-fold in culture was unsuccessful. Cell cycle
analyses then revealed that, following transfection with a
TDG expressing construct, a fraction of cells accumulated
speciﬁcally in S-phase of the cell cycle. This, however, was
not observed in cell populations transfected with a
catalytically inactive variant of TDG (Figure 1A),
although transient expression levels were equally high.
As previously observed (13), overexpressed TDG localized
strictly to the cell nucleus (data not shown). Upon
cultivation of the cells under conditions selecting for
stable TDG expression, this cell cycle eﬀect disappeared
concomitantly with the drop of TDG protein to 55-fold
the endogenous level (Figure 1B). These observations
indicated that high levels of TDG lead to a disturbance of
S-phase progression, thus conferring a selective advantage
to low TDG expressing cells, i.e. the loss of high
expressing cells, in the culture.
These ﬁndings prompted us to examine whether TDG
expression underlies cell cycle regulation. To this end, we
made use of two stably transfected HeLa cell populations,
one expressing an N-terminally HA-tagged TDG from an
SV40 promoter at  5-fold the level of the endogenous
protein (10), the other serving as a vector control and,
thus, producing endogenous TDG only. We treated these
cells with hydroxyurea (HU) or nocodazole (NO) to
induce S- or G2/M-phase arrests, respectively, and then
assessed TDG protein levels in denaturing cell extracts by
immunoblotting with anti-TDG or anti-HA antibodies.
To monitor the cell cycle status, we probed the membranes
additionally with antibodies against cyclin E or cyclin B1
(Figure 2A). This showed that endogenous (Figure 2B) as
well as ectopically expressed (Figure 2C) TDG was
Figure 1. 293T cells expressing high levels of TDG accumulate
in S-phase. (A) 293T cells were transiently co-transfected with a
plasmid overexpressing either active HA-TDG (pTDG), the catalyti-
cally inactive variant HA-TDG/N140A (pTDG
N140A), or a vector
control (pHH), and a EGFP expressing plasmid at a 10:1 ratio. The
histogram shows the cell cycle distribution of transfected cells gated for
EGFP positive cells, as determined by ﬂow cytometry. The bottom
panel documents TDG protein levels of the respective total cell
population as determined by western blotting. TDG levels in cell
populations carrying the overexpression construct were elevated by
20–30-fold. High levels of HA-TDG expression signiﬁcantly increased
the fraction of S-phase cells. This change in cell cycle distribution
required TDG to be active, as overexpression of HA-TDG/N140A
failed to produce the same eﬀect. (B) The histogram shows the cell
cycle distribution of 293T cells expressing active HA-TDG (pTDG) two
days after transfection (2d) or after two weeks of selection for stable
expression (2w). A vector control was also included (pHH). TDG
expression levels are documented by western blots in the bottom panel.
Shortly after transfection, TDG protein levels were 20–30 times higher
than normal, but dropped to about three times the amount of
endogenous TDG after selection. Concomitantly, the cell cycle eﬀect
seen after transfection disappeared. P-values (asterisk) were obtained
by the Fisher’s exact test from contingency tables comparing the
distributions of G1-, S- and G2-cells. (Open circle) Unspeciﬁc cross-
reaction of the primary antibody. (Filled square) Faster migrating
forms of TDG. HA-/TDG-S: SUMO-modiﬁed HA-TDG and endo-
genous TDG, respectively.
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TDG signals likely reﬂected traces of protein from
contaminating G2/M cells, as indicated by the low
amounts of cyclin B1 in these extracts. Base excision
assays with nuclear extracts (12) then revealed a425-fold
reduction of G T glycosylase activity in HU-arrested
HeLa cells (Figure 2D), and this correlated directly with
the decline of TDG protein. MBD4, another mismatch-
speciﬁc thymine-DNA glycosylase (5), did not contribute
notably to G T processing in these extracts (Figure 2D).
Given the slight enrichment of the enzyme in S-phase
arrested cells and that recombinant MBD4 is active under
identical experimental conditions (data not shown), this
must be interpreted to mean that G T processing by BER
is largely TDG dependent and does not occur during
S-phase. By contrast, G U processing did not correlate
with TDG protein levels. Considering that these base
release reactions were done in the presence of a 4-fold
saturating amount of the UNG-inhibitory UGI peptide
and that MBD4 appears to be poorly active in these
extracts, the uracil processing observed in the S-phase
arrested cells most likely reﬂected the activity of SMUG1.
In the absence of the UGI-peptide, however, UNG2 was
clearly the predominant uracil processing activity in these
extracts (data not shown). Together, these experiments
showed that HeLa cells down-regulate TDG protein and
activity during S-phase and are able to do so even when it
is stably expressed from an SV40 promoter at levels up to
ﬁve times higher than normal.
To exclude that the HU treatment itself aﬀects TDG
stability, we examined its levels in synchronously cycling
cell populations. Mitotic shake oﬀ experiments with
HeLaS3 cells conﬁrmed that TDG protein peaks during
G1 and drops in S-phase (Figure 3A). Here, the
disappearance of TDG coincided with the appearance of
cyclin A (14), suggesting that downregulation occurs at
the G1/S boundary. This experiment also conﬁrmed the
strict cell cycle regulation of the nuclear form of the highly
eﬃcient UNG (8,9) and thus, established that the
expression of TDG and UNG2 is perfectly anti-cyclic
with at most two short phases of overlap in late G1 and
early G2 of the cell cycle.
Next, we performed immunoﬂuorescence (IF) micro-
scopy to correlate TDG expression with the PCNA status
in an asynchronous HeLa cell population. This conﬁrmed
the absence of TDG from nuclei with focal PCNA pattern,
i.e. from S-phase nuclei (Figure 3B). Ninety-two percent
of cells with PCNA foci were TDG negative, whereas 96%
of cells with diﬀuse PCNA staining had a strong nuclear
TDG signal. Moreover, more than two-thirds of the nuclei
with PCNA foci were in an early stage of DNA replication
(15) and the vast majority of them (89%) were TDG
negative. Together, these data establish that the decline of
TDG in HeLa cells occurs at the G1–S transition, the
latest in early S-phase.
Finally, we ascertained the cell cycle regulation of TDG
in human primary ﬁbroblasts. We synchronized MRC5
cells in early S-phase by serum starvation and mimosine
treatment (16) and extracted protein and RNA from
cells harvested at diﬀerent time points following release
into S-phase. Examination of the protein extracts by
immunoblotting then showed that TDG was virtually
undetectable at the mimosine block and for 10h post-
release (Figure 4A). According to the cyclin E and B1
expression patterns, this time period represented the
progression of the cell population through S-phase. In
G2, the TDG levels started to increase until they reached a
maximum in the subsequent G1-phase. Examination of
the steady-state levels of the TDG transcript by northern
blotting showed only marginal ﬂuctuations throughout
Figure 2. TDG is absent in S-phase arrested HeLa cells. (A) Schematic
illustration of expression of cyclin E, cyclin A and cyclin B during the
cell cycle. (B and C) HeLa cells expressing endogenous TDG alone or
together with HA-TDG were blocked in S-phase with hydroxyurea
(HU) or in G2/M with nocodazole (NO). Untreated asynchronous cells
(-) and DMSO (DM) mock-treated cells were analysed in parallel.
Denaturing cell extracts were examined by western blotting with
antibodies against TDG or the HA-tag as indicated. Antibodies against
Cyclin E and Cyclin B1 were applied to monitor the cell cycle arrest;
b-tubulin staining served as a loading control. A monoclonal anti-TDG
antibody (TDGmab) detected endogenous TDG in extracts of untreated,
mock treated or G2/M arrested cells, but none in extracts from S-phase
arrested cells (B). Ectopically expressed HA-TDG also declined in HU
arrested cells, although faint TDG (TDGmab) and HA- (HAmab)-
speciﬁc signals were still discernible (C). (D) Base release assays with
a ﬂuorescent-labelled synthetic 60-mer DNA duplex document a
signiﬁcant reduction of G T processing activity in nuclear extracts
from HU-arrested HeLa cells. The assay was done with 25mgo f
nuclear extract supplemented with 2U of UNG2 inhibitory UGI
peptide. A denaturing polyarcylamide gel with the intact DNA strand
migrating at the top (S) and the cleaved products occurring as a
consequence of G T processing (P) are shown. Immunoblots of the
corresponding cell extracts with TDG and MBD4-speciﬁc antibodies
are shown on the right. (Filled square) Faster migrating forms of TDG.
HA-/TDG-S: SUMO-modiﬁed HA-TDG and endogenous TDG,
respectively.
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dramatic changes seen at the protein level. Hence, cell-
cycle-dependent expression of TDG applies to diﬀerent
human cell types and does not involve regulation at the
levels of promoter activity or mRNA stability.
TDG is targetedby ubiquitin forproteasomal degradation
We then addressed a possible role of posttranslational
modiﬁcations in the regulation of TDG. To examine
whether the glycosylase is subject to degradation by the
ubiquitin–proteasome system (17), we measured the eﬀect
of MG132, a reversible inhibitor of the 26S proteasome,
on the TDG protein level in asynchronously proliferating
HeLa cells. Cells treated with MG132 had clearly elevated
steady-state levels of TDG (Figure 5A). This eﬀect,
however, was only apparent when extracts were prepared
under denaturing conditions, the reason being a change in
TDG solubility upon proteasome inhibition. While TDG
extracted predominantly in the soluble protein fraction in
untreated cells, a substantial amount became insoluble
after MG132 treatment (Figure S1A), just like the
majority of ubiquitin-conjugated proteins (Figure S2B).
Following these indications for ubiquitylation of TDG, we
prepared denaturing extracts from HeLa cells, again
expressing either endogenous TDG alone or together
with HA-TDG, for immunoprecipitation (IP). IP with an
aﬃnity-puriﬁed polyclonal TDG antibody then led to the
expected enrichment of the glycosylase as evident from
immunoblotting with a monoclonal TDG antibody
(Figure 5B, left panel). The same antibody, however,
Figure 3. Cell cycle regulation of TDG in non-arrested cells.
(A) HeLa S3 cells were synchronized by mitotic shake oﬀ.
Following re-plating, TDG, UNG2 and MBD4 expression was
examined in a time course (TC) of 21h. At the time point indicated,
cell extracts were prepared under denaturing conditions and
analysed by western blotting with speciﬁc antibodies as indicated
on the left. The cell cycle phases indicated at the bottom were
deduced from the expression of cyclin A (S–G2/M) and E (G1–S).
b-tubulin detection served as loading control. The monoclonal
anti-TDG antibody detected TDG in mitotic and G1 cells (TC 0-9)
and in G2/M cells (TC 18). No TDG was detectable in S-phase cells
(TC 12,15). The disappearance of TDG at 12h coincided with the
de novo expression of cyclin A, indicating a downregulation of
TDG at the G1/S boundary. By contrast, nuclear UNG2 was
detectable between 9 and 18h with a peak at 12h, representing cells
in S-phase. Mitochondrial UNG1 did not ﬂuctuate throughout the
cell cycle, nor did MBD4, which shows only slightly increased
expression around S-phase. (B) Immunoﬂuorescence staining of
endogenous TDG and PCNA illustrate the absence of TDG
from S-phase nuclei. Upper cell, TDG positive cell with diﬀuse
PCNA staining; lower cell, TDG negative cell with PCNA staining
indicating early to mid S-phase; middle cell, TDG negative
cell with fewer and larger PCNA foci indicating late S-phase.
Shown are typical events of 500 randomly chosen cells scored and
classiﬁed as indicated in the table at the bottom. Asterisk: statistically
signiﬁcant diﬀerence, P50.0001 by contingency tables and Fisher’s
exact test; TDG-S: endogenous TDG modiﬁed with SUMO.
Figure 4. TDG protein levels ﬂuctuate during the cell cycle in primary
cells but mRNA is constitutively transcribed. MRC5 primary ﬁbro-
blasts were synchronized in early S-phase by serum starvation and
mimosine treatment. (A) Western blot analyses of protein extracts
prepared from asynchronous cells (AS), serum starved cells (ST) and
cells harvested at indicated times (TP hours) after release from the
mimosine block. Proteins examined were endogenous TDG, Cyclin E,
Cyclin B1 and b-tubulin as a loading control. TDG-speciﬁc signals
appeared at 12h after release into S-phase and increased gradually to
the levels found in the asynchronous culture. Expression of cyclin
E and cyclin B1 coincided with the lack or the presence of TDG,
respectively. (B) Northern blot analysis of TDG and GAPDH mRNAs
(loading control) at corresponding time points, showing that TDG-
speciﬁc mRNA was detectable throughout the cell cycle. TDG-S:
endogenous TDG modiﬁed with SUMO.
3864 Nucleic Acids Research, 2007, Vol. 35, No. 11also detected a smear of high molecular weight proteins in
the TDG-IP’s from extracts of proteasome inhibited cells.
These signals were more pronounced in the extracts
containing additional HA-TDG. Probing of the mem-
brane with a speciﬁc anti-ubiquitin antibody revealed
proteins at high molecular weight, resembling the pattern
observed with the TDG antibody (Figure 5B, right panel).
Thus, polyubiquitylated protein species co-precipitated
with a TDG-speciﬁc antibody from extracts of proteasome
inhibited cells. Unspeciﬁc binding of ubiquitylated pro-
teins to the beads did not occur (see control IP), and, given
the denaturing conditions applied for extract preparation,
unspeciﬁc binding of ubiquitylated proteins to TDG can
also be virtually excluded. We therefore conclude that the
proteins recognized by the anti-ubiquitin antibody must
be TDG isoforms carrying polyubiquitin chains of
diﬀerent lengths. To formally prove its susceptibility to
ubiquitin conjugation, we subjected bacterially produced
TDG to ubiquitylation in an in vitro reconstituted assay.
This indeed produced TDG isoforms of increased
molecular weight (Figure 5C). The reaction, however,
was ineﬃcient, indicating that ubiquitylation in vivo may
require priming of TDG, possibly by phosphorylation, to
stimulate its interaction with an E3 ubiquitin ligase (18).
Taken together, our data strongly suggest that polyubiq-
uitylation and proteasomal degradation is the mechanism
underlying the disappearance of TDG at the G1/S
boundary of the cell cycle. TDG was also shown to be
target for SUMO conjugation in cells (10). To address
whether SUMO modiﬁcation contributes to the cell cycle
regulation of TDG, we examined the behaviour of an
ectopically expressed SUMOylation-deﬁcient TDG var-
iant (HA-TDG
K330A) upon HU or NO treatment of the
cells. The protein was absent from S-phase cells and
enriched at the G2/M stage, exactly as the wild-type
control (Figure S1C), establishing that SUMO modiﬁca-
tion neither positively nor negatively interferes with TDG
ubiquitylation and proteasome degradation.
DISCUSSION
Our data establish that two prominent members of the
UDG family, TDG and UNG2, underlie strict anticyclic
cell cycle regulation. While TDG is highly expressed
throughout the G2-M and G1 phases its levels rapidly
Figure 5. TDG is polyubiquitylated and stabilized by proteasome inhibition. (A) Asynchronous HeLa cultures were treated with the proteasome
inhibitor MG132 (20mM) or DMSO. Cell extracts prepared under denaturing conditions were analysed by western blotting with a polyclonal
anti-TDG (TDGab) and an anti-b-tubulin antibody (b-tubab). SUMOylated and unmodiﬁed TDG increased after proteasome inhibition. (B) HeLa
cells stably transfected with a HA-TDG (pTDG) expression construct or the vector (pHH) were treated with MG132 or DMSO. Cell extracts
prepared under denaturing conditions were subjected to TDG-IP with an aﬃnity puriﬁed polyclonal anti-TDG antibody (TDGab). Bound protein
fractions were analysed by western blotting with the monoclonal anti-TDG (TDGmab, left panel) or an anti-ubiquitin antibody (ubiquitinab, right
panel). Strong signals appeared in the TDG-IPs but none in the IP-controls. TDG-speciﬁc signals smearing towards higher molecular weights
indicated an accumulation of modiﬁed TDG in extracts of MG132 treated cells. The anti-ubiquitin antibody detected proteins with comparable
migration properties in the corresponding TDG-IP protein fractions. (C) 10ng of puriﬁed recombinant TDG were subjected to in vitro
ubiquitylation. Shown is a western blot with the polyclonal anti-TDG antibody of aliquots taken at 0 and 2h of incubation, and of a control reaction
lacking TDG. The appearance of TDG-dependent high molecular weight bands after 2h indicates ubiquitylation of TDG. (Asterisk), protein
co-precipitating in TDG-IP and cross-reacting with the secondary antibody used; (Open circle) Components of the ubiquitylation system cross-
reacting with the anti-TDG antibody.
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rise above background. The UNG2 protein then peaks
at the beginning of S-phase and gradually declines
towards termination of DNA replication (see also
reference 9), when TDG expression resumes. This
implicates that the two biochemically redundant UDGs
control non-redundant, cell cycle stage-speciﬁc pathways
for uracil repair; while UNG2 is active during DNA
replication, TDG functions in non-replicating DNA,
notably, when U arises mainly through deamination of
cytosine. Strikingly, although the pattern of cell cycle
regulation of the two UDGs is diametrically opposed, the
underlying mechanism appears to be the same. As shown
here for TDG and reported previously for UNG2 (9),
both are subject to cell cycle controlled ubiquitylation and
proteasome degradation. Thus, the ubiquitin–proteasome
system appears to be at the heart of the coordination of
redundant BER pathways, which would be an as yet
unrecognized function. Whether this interesting concept of
coordination is a feature restricted to TDG and UNG2
only, or whether it applies more generally to DNA repair
remains to be resolved.
We wanted to get some insight into why TDG needs to
be eliminated before S-phase from ectopically expressing
the glycosylase to levels saturating its degradation.
TDG expression at 430-fold the endogenous level could
readily be obtained by transient transfection, and such
amounts were indeed saturating in the sense that low
amounts of the protein remained detectable in S-phase
arrested cell populations. Yet, attempts to maintain high
expression in culture failed; upon selection of stable
clones, TDG expression declined to levels 55-fold that
were compatible with complete degradation of the protein
in S-phase. Thus, the presence of TDG in S-phase seems
incompatible with cell cycle progression and proliferation,
and this is in line with the observation that 293T cells
transiently expressing high levels of wild-type TDG
accumulate in S-phase.
Interference with S-phase progression might occur at
the level of U excision (1). If misincorporated, U must be
eliminated from newly synthesized DNA in a way that is
coordinated with the replication process. Given its
enzymatic properties, TDG would be totally unsuited
for this task; by processing A U only ineﬃciently (19)
and binding to AP sites with high aﬃnity (10,20), it would
perturb the replication process. By contrast, UNG2
would be the glycosylase of choice here; it processes
U A with a comparably high rate, and it associates with
replication factors at the replication fork. Consistently,
UNG was shown to keep genomic uracil levels low
(1,8,21,22).
Considering the rather broad substrate spectrum of
TDG (19), however, its presence in S-phase might cause
other forms of interference. TDG could induce the
formation of DNA double-strand breaks either directly,
if it removed substrate bases close to each other in
opposite DNA strands, or indirectly, through the genera-
tion of replication blocking lesions such as AP sites or
single-strand breaks. The latter would be aided by
the inability of TDG to dissociate freely from AP sites
(12,20). In vitro, AP-site release is facilitated by a
SUMOylation-induced conformational change in TDG,
a rate-limiting step that appears useful for a temporary
protection of the labile intermediate in the repair process
(10,23). The protective nature of this dissociation delay,
however, may turn into a disadvantage in the context of
DNA replication; it might generate situations where TDG
is bound to AP sites in front of an approaching replication
fork where it acts as a road block, causing fork stalling
and eventually collapse.
A special case of mutagenic interference during S-phase
may relate to TDG’s ability to remove T from G T
mismatches. While this feature provides an excellent
means to counter mutagenesis by deamination of 5-meC,
it may represent a disadvantage during DNA replication,
where G T mispairs arise predominantly by DNA
polymerase errors. The inability of TDG to discriminate
between parental and newly synthesized DNA strands
would ﬁx C to T transition mutations in cases where the T
is in the parental strand. In addition, TDG induced
postreplicative G T repair in the parental DNA strand,
particularly in the parental lagging strand, could destabi-
lize the replication fork and thereby impede the replication
process. Thus, G T correction during DNA synthesis
should be left to the postreplicative mismatch repair
system, which is designed to correct the error in the newly
synthesized DNA strand.
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